Ann: Positive preclinical data for deoxymabs in vasculitis, page-53

Hi Raf,

To add, the ""sporadic issue"" was announced way after the success of the GMP production run, many people on the sidelines tipped in, many long termers added to their portfolio thinking that the risk of NOT going to clinic had been avoided, ""eventually we are here...AT LAST"" then the insider knowledge and a massive sell of occurred leaving the loyal ones well behind...

The above is not so easilly forgotten, even with a successful GMP with PAB's recent history there is no g/tee we will make the clinic this year....
If the GMP is a success then we are on the right track but how far will this push the SP up before the clinic and i would assume a reasonably sized CR will follow before we get there..
No point guessing on a failure as we all know that scenario..

So imho opinion until we get to the clinic and start the treatment PAB's SP will only gains will be limited and sold into heavily at resistance points....

The Dr has now got to step up and hopefully has used this time to plan out how he is going to multiply this lowly SP..

Results by end of Q2???????????????/....Not a chance, but hopefully not too long after, considering we didnt get to start the GMP until near the end of March...The Dr did say that if any major delys occur he would inform the market...

If we get the results by end of July and its good, it doesnt leave long to secure extra funding(i would assume the Dr would give us all the same deal to help with dilution)this will take a minimum of 6-8 weeks and then all the clinics and patients to be found and trial started by q3-4......Looking very doubtful for this year....


Lets hope the Dr's past credentials that Fact Finder posted come to fruition and he can add more positive stuff to his CV instead of leaving the negative stuff out of it..